In today’s world, brimful as it is with opinion and falsehoods masquerading as facts, you’d think the one place you can depend on for verifiable facts is science.

You’d be wrong. Many billions of dollars’ worth of wrong.

A few years ago, scientists at the Thousand Oaks biotech firm Amgen set out to double-check the results of 53 landmark papers in their fields of cancer research and blood biology.

The idea was to make sure that research on which Amgen was spending millions of development dollars still held up. They figured that a few of the studies would fail the test - that the original results couldn’t be reproduced because the findings were especially novel or described fresh therapeutic approaches.

But what they found was startling: Of the 53 landmark papers, only six could be proved valid.

‘Even knowing the limitations of preclinical research,’ observed C. Glenn Begley, then Amgen’s head of global cancer research, ‘this was a shocking result.’

Unfortunately, it wasn’t unique. A group at Bayer HealthCare in Germany similarly found that only 25% of published papers on which it was basing R&D projects could be validated, suggesting that projects in which the firm had sunk huge resources should be abandoned. Whole fields of […]

Read the Full Article